Literature DB >> 19255343

Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Alan S Go1, Margaret C Fang, Natalia Udaltsova, Yuchiao Chang, Niela K Pomernacki, Leila Borowsky, Daniel E Singer.   

Abstract

BACKGROUND: Atrial fibrillation (AF) substantially increases the risk of ischemic stroke, but this risk varies among individual patients with AF. Existing risk stratification schemes have limited predictive ability. Chronic kidney disease is a major cardiovascular risk factor, but whether it independently increases the risk for ischemic stroke in persons with AF is unknown. METHODS AND
RESULTS: We examined how chronic kidney disease (reduced glomerular filtration rate or proteinuria) affects the risk of thromboembolism off anticoagulation in patients with AF. We estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation and proteinuria from urine dipstick results found in laboratory databases. Patient characteristics, warfarin use, and thromboembolic events were ascertained from clinical databases, with validation of thromboembolism by chart review. During 33,165 person-years off anticoagulation among 10,908 patients with AF, we observed 676 incident thromboembolic events. After adjustment for known risk factors for stroke and other confounders, proteinuria increased the risk of thromboembolism by 54% (relative risk, 1.54; 95% CI, 1.29 to 1.85), and there was a graded, increased risk of stroke associated with a progressively lower level of estimated glomerular filtration rate compared with a rate > or =60 mL x min(-1) x 1.73 m(-2): relative risk of 1.16 (95% CI, 0.95 to 1.40) for estimated glomerular filtration rate of 45 to 59 mL x min(-1) x 1.73 m(-2) and 1.39 (95% CI, 1.13 to 1.71) for estimated glomerular filtration rate <45 mL x min(-1) x 1.73 m(-2) (P=0.0082 for trend).
CONCLUSIONS: Chronic kidney disease increases the risk of thromboembolism in AF independently of other risk factors. Knowing the level of kidney function and the presence of proteinuria may improve risk stratification for decision making about the use of antithrombotic therapy for stroke prevention in AF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255343      PMCID: PMC2733238          DOI: 10.1161/CIRCULATIONAHA.108.816082

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

1.  Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation.

Authors:  M Wiesholzer; F Harm; G Tomasec; G Barbieri; D Putz; P Balcke
Journal:  Am J Nephrol       Date:  2001 Jan-Feb       Impact factor: 3.754

2.  Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation.

Authors:  L A Pearce; R G Hart; J L Halperin
Journal:  Am J Med       Date:  2000-07       Impact factor: 4.965

3.  Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis.

Authors:  E Vázquez; C Sánchez-Perales; F Borrego; M J Garcia-Cortés; C Lozano; M Guzmán; J M Gil; M J Borrego; V Pérez
Journal:  Am Heart J       Date:  2000-12       Impact factor: 4.749

4.  Hemostatic state and atrial fibrillation (the Framingham Offspring Study).

Authors:  D Feng; R B D'Agostino; H Silbershatz; I Lipinska; J Massaro; D Levy; E J Benjamin; P A Wolf; G H Tofler
Journal:  Am J Cardiol       Date:  2001-01-15       Impact factor: 2.778

5.  Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies.

Authors:  R G Hart; L A Pearce; V T Miller; D C Anderson; J F Rothrock; G W Albers; E Nasco
Journal:  Cerebrovasc Dis       Date:  2000 Jan-Feb       Impact factor: 2.762

6.  Aortic pulse wave velocity index and mortality in end-stage renal disease.

Authors:  Jacques Blacher; Michel E Safar; Alain P Guerin; Bruno Pannier; Sylvain J Marchais; Gérard M London
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

7.  Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  A S Go; E M Hylek; L H Borowsky; K A Phillips; J V Selby; D E Singer
Journal:  Ann Intern Med       Date:  1999-12-21       Impact factor: 25.391

8.  Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension.

Authors:  J J Mourad; B Pannier; J Blacher; A Rudnichi; A Benetos; G M London; M E Safar
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

9.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study.

Authors:  A S Go; E M Hylek; K A Phillips; L H Borowsky; L E Henault; Y Chang; J V Selby; D E Singer
Journal:  Circulation       Date:  2000-07-04       Impact factor: 29.690

10.  Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study.

Authors:  Dwayne S G Conway; Jan Heeringa; Deirdre A M Van Der Kuip; Bernard S P Chin; Albert Hofman; Jacqueline C M Witteman; Gregory Y H Lip
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

View more
  110 in total

1.  Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

Review 2.  Drug adherence in patients taking oral anticoagulation therapy.

Authors:  Sebastian Ewen; Volker Rettig-Ewen; Felix Mahfoud; Michael Böhm; Ulrich Laufs
Journal:  Clin Res Cardiol       Date:  2013-09-03       Impact factor: 5.460

3.  Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.

Authors:  Catharina Jm Klijn; Maurizio Paciaroni; Eivind Berge; Eleni Korompoki; Janika Kõrv; Avtar Lal; Jukka Putaala; David J Werring
Journal:  Eur Stroke J       Date:  2019-04-09

4.  Chronic kidney disease: Safe anticoagulation for patients with CKD--are we there yet?

Authors:  Elsayed Z Soliman
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

5.  Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.

Authors:  Farsad Afshinnia; Lixia Zeng; Jaeman Byun; Crystal A Gadegbeku; Maria Chiara Magnone; Carl Whatling; Barbara Valastro; Matthias Kretzler; Subramaniam Pennathur
Journal:  Am J Nephrol       Date:  2017-07-01       Impact factor: 3.754

Review 6.  Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores.

Authors:  Shadi Yaghi; Hooman Kamel
Journal:  Stroke       Date:  2017-09-15       Impact factor: 7.914

7.  Anticoagulating atrial fibrillation patients: is there a kidney-friendly choice?

Authors:  Chun-Yih Hsieh
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 8.  Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Authors:  Tatjana S Potpara; Charles J Ferro; Gregory Y H Lip
Journal:  Nat Rev Nephrol       Date:  2018-03-26       Impact factor: 28.314

9.  Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREAtinine Measurements (SCREAM) Project.

Authors:  Juan Jesus Carrero; Marco Trevisan; Manish M Sood; Peter Bárány; Hong Xu; Marie Evans; Leif Friberg; Karolina Szummer
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-20       Impact factor: 8.237

Review 10.  Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.

Authors:  Mauro Molteni; Mario Bo; Giovanni Di Minno; Giuseppe Di Pasquale; Simonetta Genovesi; Danilo Toni; Paolo Verdecchia
Journal:  Intern Emerg Med       Date:  2017-04-24       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.